Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (51-60 of 440) with videos related to

Pageof 44
Sort By:
Oncology (Williston Park, N.Y.)|May 19, 2016
Novel Combination Treatments in Multiple MyelomaAjay K Nooka, Sagar Lonial
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
New Targets and New Agents in High-Risk Multiple MyelomaAjay K Nooka, Sagar Lonial
Blood|November 12, 2020
We need CD38 STAT-JAKBenjamin G Barwick, Sagar Lonial
Future Oncology (London, England)|November 29, 2007
PI3 kinase/AKT pathway as a therapeutic target in multiple myelomaR Donald Harvey, Sagar Lonial
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
High-risk multiple myeloma: does it still exist?Sascha A Tuchman, Sagar Lonial
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Integration of Novel Agents into the Care of Patients with Multiple MyelomaRobert Z Orlowski, Sagar Lonial
Med (New York, N.Y.)|September 14, 2024
How to rescue a DreaMM deferred …Nisha S Joseph, Sagar Lonial
Seminars in Oncology|October 19, 2013
The future of drug development and therapy in myelomaSagar Lonial, Lawrence H Boise
Oncology (Williston Park, N.Y.)|September 5, 2014
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myelomaSagar Lonial, Lawrence H Boise
Hematology. American Society of Hematology. Education Program|December 6, 2015
Novel combination approaches for myelomaSagar Lonial, Ajay K Nooka
Pageof 44

Showing results (51-60 of 440) with videos related to

Sort By:
Pageof 44
Oncology (Williston Park, N.Y.)|May 19, 2016
Novel Combination Treatments in Multiple MyelomaAjay K Nooka, Sagar Lonial
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
New Targets and New Agents in High-Risk Multiple MyelomaAjay K Nooka, Sagar Lonial
Blood|November 12, 2020
We need CD38 STAT-JAKBenjamin G Barwick, Sagar Lonial
Future Oncology (London, England)|November 29, 2007
PI3 kinase/AKT pathway as a therapeutic target in multiple myelomaR Donald Harvey, Sagar Lonial
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
High-risk multiple myeloma: does it still exist?Sascha A Tuchman, Sagar Lonial
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Integration of Novel Agents into the Care of Patients with Multiple MyelomaRobert Z Orlowski, Sagar Lonial
Med (New York, N.Y.)|September 14, 2024
How to rescue a DreaMM deferred …Nisha S Joseph, Sagar Lonial
Seminars in Oncology|October 19, 2013
The future of drug development and therapy in myelomaSagar Lonial, Lawrence H Boise
Oncology (Williston Park, N.Y.)|September 5, 2014
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myelomaSagar Lonial, Lawrence H Boise
Hematology. American Society of Hematology. Education Program|December 6, 2015
Novel combination approaches for myelomaSagar Lonial, Ajay K Nooka
Pageof 44